Bimagrumab

Drug Profile

Bimagrumab

Alternative Names: BYM-338

Latest Information Update: 27 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator MorphoSys; Novartis
  • Developer Novartis
  • Class Monoclonal antibodies
  • Mechanism of Action Type II-B activin receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Inclusion body myositis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Cachexia; Muscular atrophy; Type 2 diabetes mellitus
  • Discontinued Inclusion body myositis

Most Recent Events

  • 09 Jun 2017 Adverse events and pharmacodynamics data from a clinical trial in Healthy volunteers presented at the 77th Annual Scientific Sessions of the American Diabetes Association (ADA-2017)
  • 13 Feb 2017 Novartis completes a phase IIb/III extension trial for Inclusion body myositis (In adults, In the elderly) in USA, Australia, Japan, Belgium, Denmark, Italy, Netherlands, United Kingdom, Switzerland and France (IV) (NCT02573467)
  • 27 Jan 2017 Discontinued - Phase-III for Inclusion body myositis (In the elderly, In adults) in Belgium, Denmark, Italy, Japan, Netherlands, United Kingdom, France, Germany, Poland, Switzerland, Australia, USA (IV) (Novartis 20-F filed in 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top